SCHEMBL13630948

SCHEMBL13630948

COC(=O)c1sc(-c2ccc(NC(=O)c3cccs3)cc2)cc1N(C(C)C)C(O)[C@H]1CC[C@H](C)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.45
KMT2A Q03164 6/20 0.43
SMN1; SMN2 Q16637 5/20 0.43
MEN1 O00255 5/20 0.43
MAPT P10636 5/20 0.43
HSD17B10 Q99714 2/20 0.43
LMNA P02545 2/20 0.43
USP2 O75604 2/20 0.43
HTT P42858 1/20 0.43
RAB9A P51151 9/20 0.42
NPC1 O15118 7/20 0.42
TP53 P04637 2/20 0.42
KDM4E B2RXH2 3/20 0.41
NPSR1 Q6W5P4 1/20 0.41
ALDH1A1 P00352 2/20 0.41
HPGD P15428 2/20 0.41
POLB P06746 1/20 0.41
TDP1 Q9NUW8 1/20 0.39
NFKB1 P19838 1/20 0.38
NFKB2 Q00653 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2434497 0.85 PTPN1 (0.45) PTPN1KMT2ASMN1; SMN2MEN1MAPT
SCHEMBL2434499 0.85 PTPN1 (0.45) PTPN1KMT2ASMN1; SMN2MEN1MAPT
SCHEMBL2429262 0.77 NPC1 (0.45) KMT2ASMN1; SMN2MEN1MAPTHSD17B10
SCHEMBL2429265 0.77 NPC1 (0.45) KMT2ASMN1; SMN2MEN1MAPTHSD17B10
SCHEMBL2435331 0.71 KDM4E (0.38) PTPN1KMT2AMAPTHTTRAB9A
SCHEMBL2435327 0.71 KDM4E (0.38) PTPN1KMT2AMAPTHTTRAB9A
SCHEMBL2432670 0.70 PTPN1 (0.46) PTPN1SMN1; SMN2MAPTHSD17B10HTT
SCHEMBL2432538 0.70 MEN1 (0.45) PTPN1KMT2ASMN1; SMN2MEN1HSD17B10
SCHEMBL2432534 0.70 MEN1 (0.45) PTPN1KMT2ASMN1; SMN2MEN1HSD17B10
SCHEMBL2432673 0.70 PTPN1 (0.46) PTPN1SMN1; SMN2MAPTHSD17B10HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090274655-A1 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS SMITHKLINE BEECHAM CORPORATION 2009-11-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090274655-A1 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS EIF2AK2, HAVCR2, GTF3C2 PTPN1 622/4885KMT2A 2967/4885SMN1; SMN2 1772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.